- Merck (MRK, Financial) is expected to report a slight decline in first-quarter earnings.
- Analyst forecasts suggest a potential 40.30% upside in stock price.
- Merck receives an "Outperform" brokerage consensus rating.
Pharmaceutical giant Merck (MRK) is poised to release its first-quarter earnings, with analysts predicting earnings per share at $2.14 and revenue of $15.33 billion. This represents a 3% decline compared to the same period last year. While Merck has a strong historical performance, its stock has recently faced challenges due to declining HPV vaccine sales and intensified competition for its cancer treatment, Keytruda.
Wall Street Analysts Forecast
According to projections by 22 analysts, the average one-year price target for Merck & Co Inc (MRK, Financial) stands at $110.25, with a high forecast of $146.00 and a low of $89.00. This average target indicates a potential upside of 40.30% from the current market price of $78.58. For more in-depth predictions, visit the Merck & Co Inc (MRK) Forecast page.
Analyzing the recommendations from 27 brokerage firms, Merck & Co Inc (MRK, Financial) has an average brokerage rating of 2.1, which translates to an "Outperform" rating. This scoring system ranges from 1 to 5, where 1 indicates a Strong Buy and 5 a Sell.
GuruFocus Fair Value Estimation
According to GuruFocus, the estimated GF Value for Merck & Co Inc (MRK, Financial) in a year is projected to be $120.94. This suggests an impressive upside potential of 53.91% from the current price of $78.5802. The GF Value is a proprietary metric estimating the fair market value at which the stock should ideally trade. This valuation is derived from historical trading multiples, previous business growth, and projected future performance. For further insights, visit the Merck & Co Inc (MRK) Summary page.
